In clinical decision-making, assessment is always necessary for making a rational therapeutic choice. It also sanctions the outcome through the use of analytical tools specifically oriented toward the disease and the patient, which both separately play a part in the broader evaluation of the clinical cost benefit ratio. However, the choice of assessment tools is not always congruent with objectives, nor consistent between similar studies, which negatively affects the reliability of such studies. In the field of neurology, patient assessment is complicated by the difficulty of trying to represent behavior and brain functions in an objective manner, since they vary according to the type of disease.
In recent years, the cost benefit ratio has become increasingly complicated, taking on complex functional, economic and social values without adequately developing the criteria for choosing patient assessment tools, thus losing some of its applications in both the choice of therapy and in verifying the effects. The objective of this Masters programme is to improve participants' knowledge of various assessment tools (tests, questionnaires and technological and clinical instruments) which have become crucially important in different areas. Then, through practical examples we will approach the "personalisation" of care and the defining of outcome criteria - the last phases of the decision-making process - according to the most modern trends in medicine. This Masters programme responds to the need and urgency to develop these skills in staff who work or will work in multidisciplinary fields for outlying medical-surgical treatments such as brain tumors, epilepsy and movement disorders.